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Open accLong-term protection of neonatal hepatitis B vaccination
in a 30-year cohort in Hong KongTo the Editor:
Universal neonatal hepatitis B (HB) vaccination programme is
effective in the control of hepatitis B virus (HBV) infection in
countries with different endemicity [1,2]. However, the long-
term protective effect of neonatal hepatitis B vaccination into
adulthood, especially in endemic areas and to subjects with high
risk of infection, remains uncertain [3]. Universal neonatal HB
vaccination programme has been introduced in Hong Kong, a
region of moderate to high endemicity of hepatitis B, since
1988. To study the long-term effect of neonatal HB vaccination
in those with high risk of HBV infection in Hong Kong, we evalu-
ated the serial changes of HBV serological markers over a 30-year
period in a cohort born to hepatitis B carrier mothers and who
received neonatal hepatitis B vaccination.
In 1983, 1112 neonates, born to hepatitis B carrier mothers in
a public hospital in Hong Kong, were recruited for a study to eval-
uate the response of passive–active hepatitis B vaccination with
hepatitis B immunoglobulin and three-dose regimen of hepatitis
B vaccines of three different schedules: conventional (0, 1, and
6 months), delayed (2, 3, and 8 months), and accelerated (0, 1,
and 2 months) [4]. HBV serological markers, including HBsAg,
antibody to surface antigen (anti-HBs) and antibody to core-anti-
gen (anti-HBc), were determined upon completion of vaccination
and at subsequent intervals up to 30 years of follow-up. Anti-HBs
positivity was deﬁned as anti-HBs level higher or equal than
10 IU/L. Anti-HBc seroconversion was deﬁned as anti-HBc posi-
tivity for two consecutive readings measured at or after the
2nd year. Upon completion of the three-dose vaccination, 1006
(92.6%) out of 1086 subjects developed anti-HBs positivity.
Thirty-nine subjects failed the vaccination and developed chronic
HBV infection, giving the HBsAg positivity rate of 3.5%. Thirty-ﬁve
(89.7%) of them were born to mothers who were also hepatitis B
e-antigen (HBeAg) positive. All of these 39 subjects were tested
HBsAg positive before the age of two, with no new infection
found at subsequent follow-up time points of years 3, 5, 7, 10,
13, 16, 21, 25, and 30 post-vaccination (Table 1). At the 30th year
of follow-up, the anti-HBs positivity rate fell to 37.4%. There were
no differences in the development of HBsAg and anti-HBsJournal of Hepatology 201
ess under CC BY-NC-ND license.positivity between subjects receiving three different vaccination
schedules (p >0.05). Ninety-seven subjects developed anti-HBc
seroconversion over the 30-year period, giving a rate of 9%
(39 subjects tested for HBsAg positive were excluded), with no
statistically signiﬁcant difference in anti-HBs positive and nega-
tive subjects (9.3% vs. 5%, p >0.05).
We described the ﬁrst study showing long-term protective
effect of neonatal HB vaccination into a cohort up to 30 years of
follow-up. While most studies reported in the literature mea-
sured immune-protection by detectable levels of antibodies to
HBV [5,6], this study provided direct evidence of effective protec-
tion in subjects with high risk of infection, both via perinatal
route or close interpersonal contact with their infected mothers
and possibly other infected household members at childhood.
Among 97 subjects who developed anti-HBc seroconversion, a
majority (43%) of these seroconversions occurred at or before
year two. On the other hand, with such a long follow-up period
up to 30 years, this study also demonstrated the protective effect
of vaccine into adulthood, when the subjects might be exposed to
horizontal transmission of HBV, notably from sexual contact.
Despite the dropping rate of anti-HBs and new occurrence of
anti-HBc seroconversion over the years, there was no new devel-
opment of HBsAg positivity after the ﬁrst two years in the entire
follow-up period.
Our ﬁndings were in line with other studies which suggested
long-term protection of HB vaccine albeit with shorter follow-up
durations. Persistence of serum protective antibody level was
shown in older children or adolescents who received vaccination
at infancy [6–8]. Moreover, anamnestic response was demon-
strated in those who had lost protective antibody level, years after
vaccination [9]. A recent study further suggested that, apart from a
protective serum antibody level, cellular immune response might
also play a role for protection against HBV after vaccination [10].
There were two limitations in this study. First, subjects who
were not followed-up might have affected the overall representa-
tiveness of the data. At the 30th year of follow-up, 246 (22.1%)
subjects returned for serological tests. 372 (33.5%) subjects
defaulted follow-up, and 492 (44.2%) subjects were lost to fol-3 vol. 59 j 1360–1364 1363
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Table 1. Temporal change of hepatitis B virus serological markers in the study cohort over 30 years.
Follow-up time Baseline# Year 1 Year 2 Year 3 Year 5 Year 7 Year 10 Year 13 Year 16 Year 21 Year 25 Year 30
Total No. of subjects 1086 1075 1069 1044 953 795 792 714 610 358 278 246
Anti-HBs seroconversion 1006 
(92.6%)
980 
(91.2%)
872 
(81.6%)
766 
(73.4%)
612 
(64.2%)
477 
(60%)
355 
(44.8%)
253 
(35.4%)
203 
(33.3%)
130 
(36.3%)
103 
(37.1%)
92 
(37.4%)
HBsAg positivity 23 12 4 0 0 0 0 0 0 0 0 0
Anti-HBc seroconversion* - - 42 14 13 12 7 4 2 2 1 0**
#Upon completion of a 3-dose vaccination.
⁄Excluded 39 subjects who developed HBsAg positivity.
⁄⁄Based on one anti-HBc result.
Letters to the Editorlow-up. Two subjects died in the study period but neither of them
was known to be HB carrier. Second, the cohort received three
different vaccination schedules that different response to three
vaccination schedules could not be totally excluded.
In conclusion, this study demonstrated direct long-term efﬁ-
cacy of neonatal HB vaccination in a high-risk cohort, up to
30 years in an endemic region. The implementation of universal
neonatal HB vaccination in Hong Kong since 1988 is likely to
remain effective for long-term prevention of HBV infection in
the territory in the absence of a policy of booster in the adoles-
cent or early adult population.
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